NASDAQ:HURA TuHURA Biosciences (HURA) Stock Price, News & Analysis $3.95 +0.15 (+4.03%) Closing price 03:59 PM EasternExtended Trading$3.84 -0.12 (-2.99%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About TuHURA Biosciences Stock (NASDAQ:HURA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TuHURA Biosciences alerts:Sign Up Key Stats Today's Range$3.70▼$4.0550-Day Range$1.88▼$4.2352-Week Range$1.80▼$7.93Volume149,967 shsAverage Volume254,085 shsMarket Capitalization$172.67 millionP/E RatioN/ADividend YieldN/APrice Target$12.67Consensus RatingBuy Company OverviewTuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Read More… Receive HURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TuHURA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address HURA Stock News HeadlinesKineta Amends Merger Agreement with TuHURA BiosciencesMay 7 at 10:19 AM | tipranks.comTuHURA Biosciences, Inc. (HURA)May 6 at 3:30 PM | finance.yahoo.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Revolution we predicted has arrived." In fact, I believe these robots could impact 65 million Americans lives — by August of this year.May 8, 2025 | Weiss Ratings (Ad)Innovative Immune Therapy Approach Drives Buy Rating for TuHURA BiosciencesMay 6 at 2:43 PM | tipranks.comTuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)May 5 at 8:00 AM | prnewswire.comTuHURA And Kineta Present Updated Results From Phase I-II Study Of KVA12123April 30, 2025 | nasdaq.comTuHURA Biosciences: Promising Developments in Anti-VISTA Antibody and DNA-based Immune Activator Justify Buy RatingApril 29, 2025 | tipranks.comTuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure ...April 29, 2025 | seekingalpha.comSee More Headlines HURA Stock Analysis - Frequently Asked Questions How have HURA shares performed this year? TuHURA Biosciences' stock was trading at $4.09 at the beginning of 2025. Since then, HURA shares have decreased by 3.3% and is now trading at $3.9530. View the best growth stocks for 2025 here. Who are TuHURA Biosciences' major shareholders? Top institutional shareholders of TuHURA Biosciences include Apollon Wealth Management LLC (0.26%), Suncoast Equity Management (0.23%), Sabal Trust CO (0.09%) and Hurlow Wealth Management Group Inc. (0.07%). How do I buy shares of TuHURA Biosciences? Shares of HURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/08/2025Next Earnings (Estimated)5/13/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HURA Previous SymbolNASDAQ:HURA CIK1498382 WebN/A Phone(813) 875-6600Fax604-608-5685EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$12.67 High Stock Price Target$15.00 Low Stock Price Target$11.00 Potential Upside/Downside+231.6%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,320,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-152.88% Debt Debt-to-Equity RatioN/A Current Ratio1.54 Quick Ratio1.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.11) per share Price / Book-0.93Miscellaneous Outstanding Shares43,680,000Free Float42,200,000Market Cap$166.86 million OptionableN/A Beta0.53 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:HURA) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersIt may already be too late… A global energy shift is underway—and lithium is at the center of it. From electric vehicles to grid storage a...Huge Alerts | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredBitcoin Just Broke $100K – Are You Positioned?This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.